About | Free Trial

Last Update

2014-07-18T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Dan Shochat?

Dr. Dan Shochat

Vice President, Preclinical Development

KALOBIOS PHARMACEUTICALS INC

Direct Phone: (650) ***-****       

KALOBIOS PHARMACEUTICALS INC

442 Littlefield Avenue

South San Francisco, California 94080

United States

Company Description

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a focus on cancer. more

Find other employees at this company (77)

Background Information

Employment History

Visiting Lecturer and Adjunct Professor At the Chemistry Department

Rutgers University

Affiliations

Co-Founder
Celscia Therapeutics Inc.

Scientific Advisory Board Member
PROLOR Biotech , Inc.

Member of the Technical Advisory Committee To the Board of Directors
ANSTO Inc

Founder
Center for Molecular Medicine and Immunology

Associate Member
University of Medicine and Dentistry of New Jersey

Founder
Biotechnology Development Section

Scientific Advisory Board Member
Modigene Inc.

Scientific Advisory Board Member
Mindset BioPharmaceuticals Inc

Education

Bachelor of Science
biology
Hebrew University

Master in Science
physiology
Hebrew University

Ph.D.
Biochemistry
L.S.U. Medical School

Ph.D.
biochemistry
Louisiana State University Medical Center

Web References (27 Total References)


Management Team :: Intellect Neurosciences, Inc

www.intellectns.com [cached]

Dan Shochat, Ph.D. Vice President

Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004.
From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).


News for Friday, 10 August 2012 - www.implu.com

www.implu.com [cached]

SHOCHAT DAN, a major shareholder at KALOBIOS PHARMACEUTICALS INC


Management Team | KaloBios

kalobios.com [cached]

Dan Shochat, Ph.D.

Vice President and Head of Non-Clinical Development
Dr. Shochat has served as our Vice President and Head of Non-Clinical Development since January 2004. Prior to this, he co-founded Celscia Therapeutics in 2003 and served as Executive Vice President and Chief Technical Officer before merging Celscia with KaloBios in 2004. Dr. Shochat has 28 years of experience in the biopharmaceutical industry and 34 years of involvement in research and development of antibodies and antibody conjugates for imaging and therapy. Dr. Shochat served as Vice President of Pharmaceutical Development at Deltagen, Inc. from 2001 to 2002. In 1995, Dr. Shochat was the first employee of Coulter Pharmaceutical, Inc. as Vice President of Research and Development, and subsequently was promoted to Senior Vice President and Chief Scientific Officer. At Coulter, he led the development and manufacturing of Bexxar, a novel centrally radiolabeled monoclonal antibody. In 1988 he joined American Cyanamid to establish the Biotechnology Development Section and led it until 1995. Prior to this, Dr. Shochat established the Product R&D Group at Immunomedics Inc. and directed it from 1984 to 1988. Dr. Shochat holds a Bachelor of Science in biology and a Master in Science in physiology from the Hebrew University in Jerusalem, Israel, and a Ph.D. in biochemistry from Louisiana State University Medical Center.


Scientific Advisory Board

www.modigenetech.com [cached]

Dan Shochat, Ph.D. led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co., Dr. Shochat led the development, in collaboration with Celltech, of the first approved antibody-drug conjugate, Mylotarg®; Invented the technology and single-vial formulation, and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. Dr. Shochat is currently Executive Vice President of Development of KaloBios, Inc. Formerly, Dr. Shochat was Director, Product R&D, Immunomedics; Director of Biotechnology Development at American Cyanamid Co.; Senior Vice President and Chief Scientific Officer Coulter Pharmaceutical, Inc.; Ph.D. in Biochemistry from L.S.U. Medical School in New Orleans, LA.


Scientific Advisory Board

www.prolorbiotech.com [cached]

Dan Shochat, Ph.D. led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co., Dr. Shochat led the development, in collaboration with Celltech, of the first approved antibody-drug conjugate, Mylotarg®; Invented the technology and single-vial formulation, and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. Dr. Shochat is currently Executive Vice President of Development of KaloBios, Inc. Formerly, Dr. Shochat was Director, Product R&D, Immunomedics; Director of Biotechnology Development at American Cyanamid Co.; Senior Vice President and Chief Scientific Officer Coulter Pharmaceutical, Inc.; Ph.D. in Biochemistry from L.S.U. Medical School in New Orleans, LA.

Similar Profiles

Other People with this Name

Other people with the name Shochat

Ran Shochat
RMS Solutions LLC

Dan Shochat
ImaginAb Inc

Steven Shochat
Cactus Flower Wellness Center

Mali Shochat
Songo

Hadar Shochat
MindU Ltd

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory